SAB Biotherapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $268.0M
- Price
- $2.94
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.51%
- Volume
- 147.9K
About
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Quick stats
Shares outstanding91.0M
Computed float87.2M
Float / shares95.9%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001833214
Websitehttps://www.sab.bio
AI Summary
AI-generated1/17
minorneutralclinical trial
SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress
SAB Biotherapeutics will present encore Phase 1 data for SAB-142, its lead fully human anti-thymocyte immunoglobulin candidate for Stage 3 type 1 diabetes, at the inaugural Breakthrough T1D Clinical & Research Congress on October 9-11, 2026 in Philadelphia.
Presentations include two oral sessions covering sustained autoimmune balance with induction/maintenance dosing and C-peptide signals in adults more than 100 days post diagnosis, plus three ePosters on PK, redosing safety, and binding specificity.
SAB-142 remains in the registrational Phase 2b SAFEGUARD trial in newly diagnosed Stage 3 T1D patients; no new efficacy or safety results were disclosed in this announcement.